延长疗程贝曲沙班与短疗程依诺肝素在重症内科患者静脉血栓栓塞预防中的比较:APEX试验亚组研究
该研究为APEX试验的亚组分析,纳入703例入住ICU的重症患者,其中547例无严重肾功能不全或未使用P-糖蛋白抑制剂者进入全剂量层。比较贝曲沙班35-42天与依诺肝素10±4天。在35-42天,贝曲沙班降低静脉血栓栓塞风险(4.27% vs 7.95%,P=0.042),大出血无显著增加(1.14% vs 3.13%,P=0.07);全剂量层静脉血栓栓塞(3.32% vs 8.33%,P=0.013)和大出血(0.00% vs 3.26%,P=0.003)均降低;非大出血增多(总体2.56% vs 0.28%,P=0.011;全剂量层3.32% vs 0.36%,P=0.010);死亡率无显著差异。作者认为这些产生假设的发现需未来研究验证。
要点
- 在703例重症内科患者中,35-42天时贝曲沙班较依诺肝素降低静脉血栓栓塞风险(4.27% vs 7.95%,P=0.042),大出血无显著差异(1.14% vs 3.13%,P=0.07)。
- 全剂量层547例中,贝曲沙班降低静脉血栓栓塞(3.32% vs 8.33%,P=0.013)和大出血(0.00% vs 3.26%,P=0.003)。
- 贝曲沙班组非大出血多于依诺肝素组(总体2.56% vs 0.28%,P=0.011;全剂量层3.32% vs 0.36%,P=0.010)。
- 研究结束时死亡率两组相似(总体13.39% vs 16.19%,P=0.30;全剂量层13.65% vs 16.30%,P=0.39)。
- 作者指出获益主要来自预防无症状血栓,但被非大出血风险增加所抵消,且APEX试验未按ICU入住分层,本亚组为高度选择人群,需未来研究验证。
适用人群与场景
- APEX试验随机了7513例急性内科住院患者,本分析纳入其中703例入住ICU的重症患者。
- 547例无严重肾功能不全或未使用P-糖蛋白抑制剂的患者纳入全剂量层分析。
处置流程与药物剂量
- 贝曲沙班组:延长疗程35-42天;依诺肝素组:10±4天;具体剂量原文未写明。
研究设计与关键结果
- 研究类型:APEX试验亚组分析;总体人群703例,全剂量层547例;干预为贝曲沙班35-42天 vs 依诺肝素10±4天;主要终点为35-42天和77天时的静脉血栓栓塞、出血、净临床获益和死亡率。
- 35-42天时,贝曲沙班组静脉血栓栓塞风险低于依诺肝素组(4.27% vs 7.95%,P=0.042),大出血无显著差异(1.14% vs 3.13%,P=0.07)。
- 全剂量层中,贝曲沙班组静脉血栓栓塞(3.32% vs 8.33%,P=0.013)和大出血(0.00% vs 3.26%,P=0.003)均低于依诺肝素组。
- 贝曲沙班组非大出血多于依诺肝素组(总体:2.56% vs 0.28%,P=0.011;全剂量层:3.32% vs 0.36%,P=0.010)。
- 研究结束时死亡率两组相似(总体:13.39% vs 16.19%,P=0.30;全剂量层:13.65% vs 16.30%,P=0.39)。
证据类型、等级与局限
- 证据类型:随机对照试验APEX的亚组分析(NCT01583218);原文未给出证据等级。
- 局限:APEX试验未按ICU入住分层;本亚组为高度选择的重症患者人群;作者指出这些产生假设的发现需未来研究验证。
对床旁实践的改变
- 作者认为,与短疗程依诺肝素相比,延长疗程贝曲沙班可减少重症内科患者的静脉血栓栓塞且不增加大出血,但获益主要来自预防无症状血栓,并被非大出血风险增加所抵消。
- 作者指出这些产生假设的发现需未来研究验证,未据此给出推荐。
指南或共识出处
- APEX试验(NCT01583218)亚组研究,发表于Intensive Care Med。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To assess the efficacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxis among critically ill patients.
METHODS: The APEX trial randomized 7513 acutely ill hospitalized patients to betrixaban for 35-42 days or enoxaparin for 10 ± 4 days. Among those, 703 critically ill patients admitted to the intensive care unit were included in the analysis, and 547 patients who had no severe renal insufficiency or P-glycoprotein inhibitor use were included in the full-dose stratum. The risk of VTE, bleeding, net clinical benefit (composite of VTE and major bleeding), and mortality was compared at 35-42 days and at 77 days.
RESULTS: At 35-42 days, extended betrixaban reduced the risk of VTE (4.27% vs 7.95%, P = 0.042) without causing excess major bleeding (1.14% vs 3.13%, P = 0.07). Both VTE (3.32% vs 8.33%, P = 0.013) and major bleeding (0.00% vs 3.26%, P = 0.003) were decreased in the full-dose stratum. Patients who received betrixaban had more non-major bleeding than enoxaparin (overall population: 2.56% vs 0.28%, P = 0.011; full-dose stratum: 3.32% vs 0.36%, P = 0.010). Mortality was similar at the end of study (overall population: 13.39% vs 16.19%, P = 0.30; full-dose stratum: 13.65% vs 16.30%, P = 0.39).
CONCLUSIONS: Compared with shorter-duration enoxaparin, critically ill medical patients who received extended-duration betrixaban had fewer VTE without more major bleeding events. The benefit of betrixaban was driven by preventing asymptomatic thrombosis and offset by an elevated risk of non-major bleeding. The APEX trial did not stratify by intensive care unit admission and the present study included a highly selected population of critically ill patients. These hypothesis-generating findings need to be validated in future studies.
CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov . Unique identifier: NCT01583218.
参考来源
- Chi G, Gibson CM, Kalayci A, et al. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. Intensive Care Med. 2019. PMID: 30778649. doi:10.1007/s00134-019-05565-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。